SYMQ.Y Stock Overview
Engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SymBio Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1.21 |
| 52 Week High | JP¥1.70 |
| 52 Week Low | JP¥1.21 |
| Beta | 0.80 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| SYMQ.Y | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -3.7% | -1.6% |
| 1Y | n/a | 17.2% | 30.8% |
Return vs Industry: Insufficient data to determine how SYMQ.Y performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SYMQ.Y performed against the US Market.
Price Volatility
| SYMQ.Y volatility | |
|---|---|
| SYMQ.Y Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SYMQ.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SYMQ.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 109 | Fuminori Yoshida | www.symbiopharma.com |
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally. It offers SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administrator under the TREAKISYM name. The company also engages in the development of SyB L-1101, an intravenous formulation, which completed Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase I/II clinical trial in combination with AZA to treat HR-MDS.
SymBio Pharmaceuticals Limited Fundamentals Summary
| SYMQ.Y fundamental statistics | |
|---|---|
| Market cap | US$74.45m |
| Earnings (TTM) | -US$23.18m |
| Revenue (TTM) | US$25.02m |
3.0x
P/S Ratio-3.2x
P/E RatioIs SYMQ.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYMQ.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥3.70b |
| Cost of Revenue | JP¥761.30m |
| Gross Profit | JP¥2.93b |
| Other Expenses | JP¥6.36b |
| Earnings | -JP¥3.42b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -74.74 |
| Gross Margin | 79.40% |
| Net Profit Margin | -92.66% |
| Debt/Equity Ratio | 0% |
How did SYMQ.Y perform over the long term?
See historical performance and comparison